Adversity is less terrifying than hope: Biogen Inc (BIIB)

With 0.74 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.08 million shares. The 52-week range on BIIB shows that it touched its highest point at $319.76 and its lowest point at $220.86 during that stretch. It currently has a 1-year price target of $315.07. Beta for the stock currently stands at 0.00.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BIIB was down-trending over the past week, with a drop of -3.04%, but this was down by -6.07% over a month. Three-month performance dropped to -2.16% while six-month performance fell -11.42%. The stock lost -16.64% in the past year, while it has lost -7.14% so far this year. A look at the trailing 12-month EPS for BIIB yields 10.06 with Next year EPS estimates of 15.81. For the next quarter, that number is 3.18. This implies an EPS growth rate of -15.14% for this year and 5.46% for next year. EPS is expected to grow by 0.15% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 11.85%.

Float and Shares Shorts:

At present, 144.10 million BIIB shares are outstanding with a float of 144.03 million shares on hand for trading. On Jan 11, 2024, short shares totaled 3.76 million, which was 2.60% higher than short shares on Dec 14, 2023. In addition to BITB as the firm’s Bitwise Bitcoin ETF Common Shar, BIIB serves as its Biogen Inc..

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BIIB since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With BIIB analysts setting a high price target of $406.00 and a low target of $245.00, the average target price over the next 12 months is $315.07. Based on these targets, BIIB could surge 68.96% to reach the target high and rise by 1.96% to reach the target low. Reaching the average price target will result in a growth of 31.12% from current levels.

Summary of Insider Activity:

Insiders traded BIIB stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 34 while that of sell transactions has risen to 38 over the past year. The total number of shares bought during that period was 41,812 while 25,070 shares were sold.